DDInter1678 DDInter596
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) upregulates {v} (Gene) P4HA2
P4HA2 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) downregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) causes {v} (Side Effect) Urine abnormality
Urine abnormality {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) downregulates {v} (Gene) AURKA
AURKA {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) upregulates {v} (Gene) P4HA2
P4HA2 {u} (Gene) is upregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sirolimus {u} (Compound) downregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is upregulated by {v} (Compound) Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Sirolimus (Compound) upregulates P4HA2 (Gene) and P4HA2 (Gene) is upregulated by Doxorubicin (Compound)
Sirolimus (Compound) downregulates LRPAP1 (Gene) and LRPAP1 (Gene) is upregulated by Doxorubicin (Compound)
Sirolimus (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is downregulated by Doxorubicin (Compound)
Sirolimus (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Doxorubicin (Compound)
Sirolimus (Compound) causes Urine abnormality (Side Effect) and Urine abnormality (Side Effect) is caused by Doxorubicin (Compound)
Sirolimus (Compound) downregulates AURKA (Gene) and AURKA (Gene) is bound by Doxorubicin (Compound) and AURKA (Gene) is downregulated by Doxorubicin (Compound)
Sirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Sirolimus (Compound) upregulates P4HA2 (Gene) and P4HA2 (Gene) is upregulated by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Sirolimus (Compound) downregulates LRPAP1 (Gene) and LRPAP1 (Gene) is upregulated by Idarubicin (Compound) and Idarubicin (Compound) resembles Doxorubicin (Compound)